HIV Prevention Breakthrough: Gilead’s Lenacapavir Receives FDA Nod, Expands Global Access
In a significant advancement for global public health, Gilead Sciences has achieved a pivotal milestone with the U.S. Food and Drug Administration (FDA) approval of lenacapavir, its novel antiviral drug, for use as a preventive therapy against HIV infection. This approval, granted in June 2025, marks a new era in HIV prevention, offering a long-acting…